FMR LLC 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-08 09:09 am Purchase | 2025-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 8,928,574 11.200% | 3,048,963 (+51.86%) | Filing |
| 2025-11-05 11:40 am Purchase | 2025-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 5,879,611 8.200% | 1,470,377 (+33.35%) | Filing |
| 2025-05-12 10:36 am Sale | 2025-03-31 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 4,409,234 6.800% | -699,907 (-13.70%) | Filing |
| 2024-11-12 10:32 am Purchase | 2024-11-08 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 5,109,141 7.933% | 2,761,614 (+117.64%) | Filing |
| 2022-02-09 09:22 am Sale | 2022-02-08 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 2,347,527 4.568% | -94,533 (-3.87%) | Filing |